Emerging evidence indicates that the hepatic overexpression of CHREBP directly induces hepatic steatosis, whereas the liver-specific suppression of CHREBP in obese murine models attenuates body weight gain, redirects glucose flux toward glycogen synthesis, and mitigates lipid accumulation in the liver [29,78]. This evidence concerns the gene MLXIPL and fatty liver disease.